• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Home
  • LinkedIn
  • Twitter

  • About Us
    • Overview
    • Executive Committee
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • shRNA
      • shARC Platform
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us
  • Home
  • Investors

Investors

Investors

Corporate Profile

Celyad Oncology is a biotechnology company focused on the research and discovery of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.

EURONEXT NASDAQ
Stock Information
Financial Market Data powered by Quotemedia. All rights reserved.
View the Terms of Use. Data delayed 15 minutes unless indicated.
ISIN: BE0974260896-XBRU Updated at
See Price Chart

Financial Calendar

Mar 23, 2023

FY 2022 Financial Results

May 5, 2023

  • Annual Shareholder Meeting
  • Q1 2023 Business Update

Aug 3, 2023

H1 2023 Interim Results

Nov 9, 2023

Q3 2023 Business Update

Investors Kit

Corporate Presentation

Annual Report 2022

Upcoming Events

Sorry, no posts matched your criteria.

See More Events

Latest Financial News

23

Mar
2023

Annual Report 2022

10

Nov
2022

Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights

5

Aug
2022

Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

discover all Financial News

Footer

Celyad Oncology

Celyad Oncology Logo
  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.

  • Cookie Policy |
  • Privacy Policy |
  • Terms of Use